Major Depression Research Study
Researchers at Arch Clinical Trials are conducting a study on an investigational medication for major depressive disorder (MDD).
Fast Facts
Have Been Diagnosed With Depression
Current Depressive Episode Has Lasted at Least 4 Weeks
Compensation
Provided
Conducted in
St. Louis, MO
Study Background
This clinical research study is exploring a new oral medication for treating major depressive disorder.
A new study medication is being developed as an oral prodrug of allopregnanolone, a compound that targets depression-related brain pathways. The FDA has already approved an intravenous version of allopregnanolone for postpartum depression, and this study will evaluate how effective and safe the oral version is for adults living with major depressive disorder (MDD), with or without anxious distress.
Participants will either receive the study medication or a placebo, which looks and tastes the same but does not contain any active ingredient. The study will help researchers determine whether this oral treatment could be a future option for people struggling with depression.
Study Background
This clinical research study is exploring a new oral medication for treating major depressive disorder.
A new study medication is being developed as an oral prodrug of allopregnanolone, a compound that targets depression-related brain pathways. The FDA has already approved an intravenous version of allopregnanolone for postpartum depression, and this study will evaluate how effective and safe the oral version is for adults living with major depressive disorder (MDD), with or without anxious distress.
Participants will either receive the study medication or a placebo, which looks and tastes the same but does not contain any active ingredient. The study will help researchers determine whether this oral treatment could be a future option for people struggling with depression.
Additional Information
This study aims to learn more about the safety and effectiveness of an investigational oral medication, for treating major depressive disorder (MDD).
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Have been diagnosed with depression
- Current depressive episode has lasted at least 4 weeks
- Willing and able to refrain from the use of drugs of abuse (including recreational cannabinoids/medical cannabinoids) and alcohol for the duration of the study
- No history of bipolar disorder, schizophrenia, schizoaffective, or other psychotic disorder, obsessive-compulsive disorder, or any persistent neurocognitive disorder
- Ages 18-65
If you qualify, your participation will last about 80 days and include up to 10 study visits. The study has three phases: a screening period (up to 4 weeks), a 6-week treatment period, and a 1-week safety follow-up. You may also be eligible for a 6-week open-label extension. You will receive either the study medication or a placebo.
You will be compensated up to $1,800 for completing the study. Travel reimbursement is also available— up to $200 per day with receipts for transportation or parking. Participants can also enjoy snacks, meals, coffee, free blood work with results, ECG, vital signs, and physical exams.
There is no cost for you to participate in our research study.